Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.
Saved in:
| Title: | Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial. |
|---|---|
| Authors: | Johnson JS; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Miller JW; USF Health Morsani College of Medicine, Tampa, FL, USA., Hatoum F; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Schell MJ; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Yu X; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Roman Souza G; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Mizelle S; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Gullapalli K; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Fazili A; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Jain R; Department of Genitourinary Oncology, Weill Cornell Medicine, New York, NY, USA., Chatzkel J; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cen L; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Dhillon J; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cubitt C; Immune Monitoring Core, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Yao J; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Whiting J; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Li J; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Swank J; Department of Pharmacy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Jameel G; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Zhang J; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Wang X; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Spiess PE; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Fishman M; USF Health Morsani College of Medicine, Tampa, FL, USA.; Tampa General Hospital Cancer Institute, Tampa, FL, USA., Chahoud J; Department of Genitourinary Oncology, Orlando Health Cancer Institute, Orlando, FL, USA. Jad.Chahoud@orlandohealth.com. |
| Source: | Nature communications [Nat Commun] 2026 May 25; Vol. 17 (1). Date of Electronic Publication: 2026 May 25. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
